Back to News
investment

Nomura Mid Cap Income Opportunities Fund Q4 2025 Commentary

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
US equities climbed in Q4 2025 as AI-driven growth optimism clashed with rising concerns over profitability, spending, and macroeconomic instability, reflecting a divided investor sentiment. The Nomura Mid Cap Income Opportunities Fund underperformed its Russell Midcap Index benchmark in Q4 2025, primarily due to poor stock selection in industrials, consumer discretionary, and materials sectors. Cardinal Health saw growth gains from specialty pharmaceutical markets, offering a rare bright spot amid broader sector challenges during the quarter. Investors are shifting focus toward profitability, free cash flow, and disciplined capital allocation, signaling stricter scrutiny of corporate financial health in 2026. Macquarie Asset Management highlighted increased investor caution despite AI enthusiasm, emphasizing balancing growth potential with fiscal responsibility in volatile markets.
AI Audio Summary
0:00 / 0:00
Click to play
Untitled design (15).png
Quantum News · Media Library

Macquarie Asset Management40 FollowersFollow5ShareSavePlay(6min)CommentsSummaryUS equities rose in 4Q25 amid a complex mix of optimism about growth driven by artificial intelligence and growing concerns about profitability, spending, and macroeconomic uncertainty.In 4Q25, Nomura Mid Cap Income Opportunities Fund Institutional Class shares underperformed the Fund's benchmark, the Russell Midcap Index.Negative stock selection in industrials was the primary detractor during the quarter with adverse stock selection in consumer discretionary and materials also detracting.Cardinal Health Inc., a leading distributor of pharmaceuticals and medical products, experienced a lift in growth from specialty pharmaceutical markets.Investor focus will increasingly shift toward profitability, free cash flow generation, and disciplined capital allocation. Funtap/iStock via Getty Images Market review US equities rose in 4Q25 amid a complex mix of optimism about growth driven by artificial intelligence (AI) and growing concerns about profitability, spending, and macroeconomic uncertainty. While enthusiasm for AI investments remained a defining theme, investor scrutiny increasedThis article was written byMacquarie Asset Management40 FollowersFollowMacquarie Asset Management (MAM) is the asset management division of Macquarie Group. MAM is an integrated asset manager across public and private markets offering a diverse range of capabilities, including real assets, real estate, credit, equities and multi-asset solutions. Macquarie Group refers to Macquarie Group Limited and its subsidiaries and affiliates worldwide. Delaware Funds by Macquarie refers to certain investment solutions that MAM distributes, offers, or advises. Investment advisory services are provided to the Delaware Funds by Delaware Management Company, a series of Macquarie Investment Management Business Trust (MIMBT), a Securities and Exchange Commission (SEC) registered investment adviser.

The Delaware Funds are distributed by Delaware Distributors, L.P., a registered broker/dealer and member of the Financial Industry Regulatory Authority (FINRA) and an affiliate of MIMBT. Note: This account is not managed or monitored by Macquarie Asset Management, and any messages sent via Seeking Alpha will not receive a response. For inquiries or communication, please use the Macquarie Asset Management's official channels.

Read Original

Tags

drug-discovery

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.